Literature DB >> 22828647

Rotavirus-related hospitalizations are responsible for high seasonal peaks in all-cause pediatric hospitalizations.

Patricia Bruijning-Verhagen1, Valerie Sankatsing, Annemieke Kunst, Charlie van den Born, Esther Bleeker, Steven Thijsen, Ed P F Ijzerman, Vincent H J van der Velden, Marc J M Bonten.   

Abstract

BACKGROUND: Seasonal rotavirus (RV) epidemics partly overlap with those of other common childhood infections, thereby generating enormous, but poorly quantified, pressure on hospital resources during winter and spring. We assessed RV contribution to seasonal excess in all-cause pediatric hospitalizations and RV hospitalization incidence rate in an observational study.
METHODS: The study was conducted among pediatric wards in 3 general hospitals and 1 pediatric tertiary care center. Numbers of RV hospitalizations were determined from 5-year data on confirmed RV hospitalizations and adjusted for RV underreporting, assessed through active surveillance for acute gastroenteritis during the 2011 RV season. Incidence rate and RV contribution to all-cause hospitalizations were determined on hospital administrative data and population statistics.
RESULTS: RV accounted for 6.2% (95% confidence interval: 5.3-7.1) of all-cause pediatric hospitalizations among general hospitals and 3.1% (95% confidence interval: 2.9-3.3) at the tertiary care center, adjusted for the proportion RV underreporting among gastroenteritis patients (33%) as observed during active surveillance. Among general hospitals, there was a 30% increase in all-cause hospitalizations during the active season of common childhood infections compared with summer months. RV contributed 31% to seasonal excess in all-cause pediatric hospitalizations, representing 12.9% of hospitalizations between January and May. RV hospitalizations incidence rate in the population was 510/100,000 child-years <5 years (95% confidence interval: 420-600).
CONCLUSION: RV is one of the main causes of seasonal peaks in pediatric hospitalizations, and as such contributes significantly to periodic high bed capacity pressures and associated adverse effects. RV vaccination benefits in this respect should be considered in decision-making processes.

Entities:  

Mesh:

Year:  2012        PMID: 22828647     DOI: 10.1097/INF.0b013e31826a5ba1

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  8 in total

1.  Seasonal variation of diseases in children: a 6-year prospective cohort study in a general hospital.

Authors:  Tessa V Schrijver; Paul L P Brand; Jolita Bekhof
Journal:  Eur J Pediatr       Date:  2015-10-22       Impact factor: 3.183

2.  Validation of the modified Vesikari score in children with gastroenteritis in 5 US emergency departments.

Authors:  David Schnadower; Phillip I Tarr; Marc H Gorelick; Karen O'Connell; Cindy G Roskind; Elizabeth C Powell; Jayashree Rao; Seema Bhatt; Stephen B Freedman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-10       Impact factor: 2.839

3.  The Economic Value of Vaccination: Why Prevention is Wealth.

Authors: 
Journal:  J Mark Access Health Policy       Date:  2015-08-12

4.  Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination.

Authors:  Patricia Bruijning-Verhagen; Marie-Josée J Mangen; Mariet Felderhof; Nico G Hartwig; Marlies van Houten; Léon Winkel; Wouter J de Waal; Marc J M Bonten
Journal:  BMC Med       Date:  2013-04-26       Impact factor: 8.775

5.  Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting.

Authors:  P Bruijning-Verhagen; J A P van Dongen; J D M Verberk; R Pijnacker; R D van Gaalen; D Klinkenberg; H E de Melker; M-J J Mangen
Journal:  BMC Med       Date:  2018-09-10       Impact factor: 8.775

6.  Hospital bed occupancy for rotavirus and all cause acute gastroenteritis in two Finnish hospitals before and after the implementation of the national rotavirus vaccination program with RotaTeq®.

Authors:  Susanne Hartwig; Matti Uhari; Marjo Renko; Perrine Bertet; Maria Hemming; Timo Vesikari
Journal:  BMC Health Serv Res       Date:  2014-12-11       Impact factor: 2.655

7.  The intangible benefits of vaccination - what is the true economic value of vaccination?

Authors:  Paolo Bonanni; Juan José Picazo; Vanessa Rémy
Journal:  J Mark Access Health Policy       Date:  2015-08-12

8.  Estimated hospitalizations attributed to norovirus and rotavirus infection in Canada, 2006-2010.

Authors:  V K Morton; M K Thomas; S A McEwen
Journal:  Epidemiol Infect       Date:  2015-05-20       Impact factor: 4.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.